Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. 2009

Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
Department of Medicine, University Hospital MAS, Malmö, Sweden. Stefan.Lindgren@med.lu.se

BACKGROUND Conditions exhibiting features of two different autoimmune liver diseases are designated overlap syndromes. Variant forms display some, but not all, characteristics of a distinct autoimmune liver disease. We describe transitions over time between variant forms of PBC, i.e. AMA-negative PBC, autoimmune hepatitis (AIH)-PBC overlap and autoimmune cholangitis (AIC) in a large cohort of PBC patients in Sweden. METHODS We retrieved all patients with variant forms of PBC in six university hospitals in Sweden, covering 60% of the Swedish population. The diagnosis of PBC and its variants was based on laboratory findings and compatible histological features. The revised autoimmune hepatitis scoring system proposed by the International Autoimmune Hepatitis Group was used to establish the diagnosis of AIH. RESULTS In a population of 800 patients with PBC, we identified 35 (5%) variant forms; 25 patients with AIH-PBC overlap, 8 with AIC and 2 with AMA-negative PBC at the time of our study. The initial diagnoses were PBC (3 patients), AIH (3), AIH-PBC overlap (16), AIC (8) and AMA-negative PBC with (1) or without (4) concomitant AIH. The median follow-up was 125 (41-360) months. Immunosuppression and ursodeoxycholic acid induced a complete or good regression of increased aminotransferases in about half of the patients who were given one or both of these treatments. CONCLUSIONS Variant forms of PBC are seen in approximately 5% of PBC patients in Sweden. Transition between different forms may occur, emphasizing the value of repeat biopsies, but established overlapping AIH-PBC seems to be stable over time.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008105 Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes. Biliary Cirrhosis,Biliary Cirrhosis, Primary,Biliary Cirrhosis, Secondary,Cholangitis, Chronic Nonsuppurative Destructive,Liver Cirrhosis, Obstructive,Primary Biliary Cholangitis,Biliary Cirrhosis, Primary, 1,Primary Biliary Cirrhosis,Secondary Biliary Cholangitis,Secondary Biliary Cirrhosis,Biliary Cholangitides, Primary,Biliary Cholangitis, Primary,Biliary Cholangitis, Secondary,Cholangitides, Primary Biliary,Cholangitis, Primary Biliary,Cholangitis, Secondary Biliary,Cirrhosis, Biliary,Cirrhosis, Secondary Biliary,Liver Cirrhoses, Biliary,Obstructive Liver Cirrhosis,Primary Biliary Cholangitides,Secondary Biliary Cholangitides
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002761 Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both. Cholangitides
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
December 1991, Hepatology (Baltimore, Md.),
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
September 1973, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
December 2004, Minerva medica,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
August 1985, Gastroenterology,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
February 2005, Alimentary pharmacology & therapeutics,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
January 2006, Clinical transplantation,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
November 1985, Scandinavian journal of gastroenterology,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
October 1978, Acta hepato-gastroenterologica,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
January 1997, Journal of vascular and interventional radiology : JVIR,
Stefan Lindgren, and Hans Glaumann, and Sven Almer, and Annika Bergquist, and Einar Björnsson, and Ulrika Broomé, and Ake Danielsson, and Barbro Lebrun, and Hanne Prytz, and Rolf Olsson
June 1978, British medical journal,
Copied contents to your clipboard!